How Does the Additional Benefit Extend of Orphan Drugs Impact Price Negotiations in the German Outpatient Sector?
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1462
https://www.valueinhealthjournal.com/article/S1098-3015(16)32828-5/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1374
First Page :
A600
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32828-5&doi=10.1016/j.jval.2016.09.1462